For most of the large molecules and bio reagent projects, molecular biology is the starting point which involves construct design, gene synthesis and cloning. In addition to standard molecular biology solutions, we provide specialized services to support target identification, antibody discovery, metabolic engineering and translational research.
Our service range includes:
Recombinant DNA technology Antibody gene sequencing (high-throughput) Mutagenesis Customized Library generation Plasmid DNA preparation & scale-up for CGT requirements Microbial genome engineering Gene expression analysis IVT mRNA synthesis
Gene cloning service at Aurigene supports customized generation of recombinant constructs by various methods for generation of antibodies, enzymes, and reagent proteins:
Plasmid DNA purification service caters to both small research facilities as well as large-scale manufacturing for biotech and pharmaceutical companies:
Site-directed mutagenesis service enables life science researchers by creating specific DNA mutations for studying gene regulation, DNA-protein interactions, protein structure or function relationship, enzyme function and novel recombinant proteins:
Antibody sequence information from hybridoma is essential for protection, preservation and optimization of monoclonal antibodies (mAbs). Antibody gene sequencing and reformatting at Aurigene is a one-stop solution for recombinant expression and production of antibodies:
Experience in genome scale modification of bacterial and yeast strains for production of recombinant proteins, platform chemicals and metabolic engineering:
Constructing cDNA libraries, phage libraries and yeast libraries along with provisions for high throughput screening and functional characterization.
Regulation and expression of genes at the transcriptional and translational stages play a crucial role in determining gene function. Scientists at Aurigene carry out routine expression studies by several methods such as:
Residual host-cell proteins (HCP) and host-cell DNA (HCD) are impurities that remain in recombinant bio therapeutics. We ensure that these impurities and contaminants are detected and reduced to levels below those guided by regulatory agencies:
State-of-the-art facilities with high-end instrumentation
Wide range of tools under one umbrella
Customized generation of recombinant constructs
Fast and innovative solutions
One-stop solution for recombinant expression and production of antibodies
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.